Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults

Brittany Wippel, Kenneth Gundle, Theresa Huong Dang, Jillian Paxton, Joseph Bubalo, Linda Stork, Rongwei (Rochelle) Fu, Christopher Ryan, Lara Davis

Research output: Contribution to journalArticle

Abstract

Background: Doxorubicin, cisplatin, and high-dose methotrexate (HDMTX) are the backbone of pediatric osteosarcoma treatment. However, due to toxicity concerns and the lack of data regarding efficacy in adults, high-dose methotrexate is rarely used in the adult population. Methods: This single-center retrospective study examined 33 patients who received HDMTX (12 g/m2, maximum 20 g) for the treatment of osteosarcoma at Oregon Health and Science University (OHSU) from 2011 to 2017. Time to serum methotrexate level ≤0.1 µmol/L was the primary outcome. Secondary outcomes included number of HDMTX doses received, methotrexate-related toxicities, and disease outcomes including histologic response at resection and metastasis-free survival. Results: Median age was 20 years [range 7-38]; 14 patients ≤18 years old and 19 patients >18 years old. Median time to clearance for patients ≤18 years was 79 hours (range 63-116) compared to 120 hours (range 77-315) for patients >18 years (P < 0.001). No correlation between age and histologic response at resection was observed (P = 0.50), but there was a significant positive correlation between the number of HDMTX doses received before resection and histologic response (r = 0.49, P = 0.006). There was no significant difference in metastasis-free survival between age groups, although a trend toward improved survival was noted for patients who received at least seven doses of HDMTX. Conclusion: Age over 18 years correlates with delayed methotrexate clearance and fewer administered doses of methotrexate, without increased toxicity. The potential benefit of HDMTX in young adults with osteosarcoma may outweigh toxicity risks.

Original languageEnglish (US)
JournalCancer Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Osteosarcoma
Methotrexate
Young Adult
Safety
Survival
Neoplasm Metastasis
Doxorubicin
Cisplatin
Retrospective Studies
Age Groups
Pediatrics

Keywords

  • adolescents and young adults
  • efficacy
  • methotrexate
  • osteosarcoma
  • toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults. / Wippel, Brittany; Gundle, Kenneth; Dang, Theresa Huong; Paxton, Jillian; Bubalo, Joseph; Stork, Linda; Fu, Rongwei (Rochelle); Ryan, Christopher; Davis, Lara.

In: Cancer Medicine, 01.01.2018.

Research output: Contribution to journalArticle

@article{dac55f2534b342818d327c9eba464c01,
title = "Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults",
abstract = "Background: Doxorubicin, cisplatin, and high-dose methotrexate (HDMTX) are the backbone of pediatric osteosarcoma treatment. However, due to toxicity concerns and the lack of data regarding efficacy in adults, high-dose methotrexate is rarely used in the adult population. Methods: This single-center retrospective study examined 33 patients who received HDMTX (12 g/m2, maximum 20 g) for the treatment of osteosarcoma at Oregon Health and Science University (OHSU) from 2011 to 2017. Time to serum methotrexate level ≤0.1 µmol/L was the primary outcome. Secondary outcomes included number of HDMTX doses received, methotrexate-related toxicities, and disease outcomes including histologic response at resection and metastasis-free survival. Results: Median age was 20 years [range 7-38]; 14 patients ≤18 years old and 19 patients >18 years old. Median time to clearance for patients ≤18 years was 79 hours (range 63-116) compared to 120 hours (range 77-315) for patients >18 years (P < 0.001). No correlation between age and histologic response at resection was observed (P = 0.50), but there was a significant positive correlation between the number of HDMTX doses received before resection and histologic response (r = 0.49, P = 0.006). There was no significant difference in metastasis-free survival between age groups, although a trend toward improved survival was noted for patients who received at least seven doses of HDMTX. Conclusion: Age over 18 years correlates with delayed methotrexate clearance and fewer administered doses of methotrexate, without increased toxicity. The potential benefit of HDMTX in young adults with osteosarcoma may outweigh toxicity risks.",
keywords = "adolescents and young adults, efficacy, methotrexate, osteosarcoma, toxicity",
author = "Brittany Wippel and Kenneth Gundle and Dang, {Theresa Huong} and Jillian Paxton and Joseph Bubalo and Linda Stork and Fu, {Rongwei (Rochelle)} and Christopher Ryan and Lara Davis",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cam4.1898",
language = "English (US)",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults

AU - Wippel, Brittany

AU - Gundle, Kenneth

AU - Dang, Theresa Huong

AU - Paxton, Jillian

AU - Bubalo, Joseph

AU - Stork, Linda

AU - Fu, Rongwei (Rochelle)

AU - Ryan, Christopher

AU - Davis, Lara

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Doxorubicin, cisplatin, and high-dose methotrexate (HDMTX) are the backbone of pediatric osteosarcoma treatment. However, due to toxicity concerns and the lack of data regarding efficacy in adults, high-dose methotrexate is rarely used in the adult population. Methods: This single-center retrospective study examined 33 patients who received HDMTX (12 g/m2, maximum 20 g) for the treatment of osteosarcoma at Oregon Health and Science University (OHSU) from 2011 to 2017. Time to serum methotrexate level ≤0.1 µmol/L was the primary outcome. Secondary outcomes included number of HDMTX doses received, methotrexate-related toxicities, and disease outcomes including histologic response at resection and metastasis-free survival. Results: Median age was 20 years [range 7-38]; 14 patients ≤18 years old and 19 patients >18 years old. Median time to clearance for patients ≤18 years was 79 hours (range 63-116) compared to 120 hours (range 77-315) for patients >18 years (P < 0.001). No correlation between age and histologic response at resection was observed (P = 0.50), but there was a significant positive correlation between the number of HDMTX doses received before resection and histologic response (r = 0.49, P = 0.006). There was no significant difference in metastasis-free survival between age groups, although a trend toward improved survival was noted for patients who received at least seven doses of HDMTX. Conclusion: Age over 18 years correlates with delayed methotrexate clearance and fewer administered doses of methotrexate, without increased toxicity. The potential benefit of HDMTX in young adults with osteosarcoma may outweigh toxicity risks.

AB - Background: Doxorubicin, cisplatin, and high-dose methotrexate (HDMTX) are the backbone of pediatric osteosarcoma treatment. However, due to toxicity concerns and the lack of data regarding efficacy in adults, high-dose methotrexate is rarely used in the adult population. Methods: This single-center retrospective study examined 33 patients who received HDMTX (12 g/m2, maximum 20 g) for the treatment of osteosarcoma at Oregon Health and Science University (OHSU) from 2011 to 2017. Time to serum methotrexate level ≤0.1 µmol/L was the primary outcome. Secondary outcomes included number of HDMTX doses received, methotrexate-related toxicities, and disease outcomes including histologic response at resection and metastasis-free survival. Results: Median age was 20 years [range 7-38]; 14 patients ≤18 years old and 19 patients >18 years old. Median time to clearance for patients ≤18 years was 79 hours (range 63-116) compared to 120 hours (range 77-315) for patients >18 years (P < 0.001). No correlation between age and histologic response at resection was observed (P = 0.50), but there was a significant positive correlation between the number of HDMTX doses received before resection and histologic response (r = 0.49, P = 0.006). There was no significant difference in metastasis-free survival between age groups, although a trend toward improved survival was noted for patients who received at least seven doses of HDMTX. Conclusion: Age over 18 years correlates with delayed methotrexate clearance and fewer administered doses of methotrexate, without increased toxicity. The potential benefit of HDMTX in young adults with osteosarcoma may outweigh toxicity risks.

KW - adolescents and young adults

KW - efficacy

KW - methotrexate

KW - osteosarcoma

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=85058938124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058938124&partnerID=8YFLogxK

U2 - 10.1002/cam4.1898

DO - 10.1002/cam4.1898

M3 - Article

C2 - 30580500

AN - SCOPUS:85058938124

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -